Presented at ASH: the EPCORE FL-1 study on epcoritamab in follicular lymphoma

About this episode

Franck Morschhauser discusses the phase 3 EPCORE FL-1 study on epcoritamab for follicular lymphoma with Ben Abbott.

Franck Morschhauser joins Ben Abbott of The Lancet to discuss the phase 3 EPCORE FL-1 study on epcoritamab, lenalidomide, and rituximab for relapsed or refractory follicular lymphoma, which is being presented at ASH 2025. Click here to read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02360-8/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thela...

People in this episode

Host: Ben Abbott

Guest: Franck Morschhauser

Topics covered

• follicular lymphoma
• epcoritamab
• cancer treatment
• clinical trials
• ASH conference

Keywords

• follicular lymphoma
• epcoritamab
• lenalidomide
• rituximab
• clinical trial
• ASH 2025

Mentioned in this episode

Organizations: The Lancet

Products: epcoritamab, lenalidomide, rituximab

Books & works: EPCORE FL-1 study

More episodes of The Lancet in conversation with

• Tania Nikolcheva, Gavin Giovannoni and Tharick Pascoal on the Special issue in Neurology · May 31, 2026 · 33 min
• Paul Spiegel: rethinking the humanitarian response to conflict and forced displacement · May 19, 2026 · 32 min
• Can semaglutide be used to treat alcohol use disorder? · May 2, 2026 · 32 min
• Louise Chappell and Na’ama Carlin on Personal Cancer Stories · February 3, 2026 · 31 min
• Susannah Stanway on the London Global Cancer Week · December 19, 2025 · 24 min
• Carlos Monteiro, Camila Corvalán, and Phil Baker on Ultra-Processed Foods and Human Health · December 9, 2025 · 1h 1m